CA2997769A1 - Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents - Google Patents
Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents Download PDFInfo
- Publication number
- CA2997769A1 CA2997769A1 CA2997769A CA2997769A CA2997769A1 CA 2997769 A1 CA2997769 A1 CA 2997769A1 CA 2997769 A CA2997769 A CA 2997769A CA 2997769 A CA2997769 A CA 2997769A CA 2997769 A1 CA2997769 A1 CA 2997769A1
- Authority
- CA
- Canada
- Prior art keywords
- hydrogen
- alkyl
- compound according
- optionally substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216168P | 2015-09-09 | 2015-09-09 | |
| US62/216,168 | 2015-09-09 | ||
| PCT/US2016/050685 WO2017044567A1 (en) | 2015-09-09 | 2016-09-08 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2997769A1 true CA2997769A1 (en) | 2017-03-16 |
Family
ID=56940436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2997769A Abandoned CA2997769A1 (en) | 2015-09-09 | 2016-09-08 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10221158B2 (enExample) |
| EP (1) | EP3347350A1 (enExample) |
| JP (1) | JP6966425B2 (enExample) |
| CN (1) | CN108349943A (enExample) |
| CA (1) | CA2997769A1 (enExample) |
| WO (1) | WO2017044567A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015138500A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents |
| CN106458916A (zh) | 2014-03-11 | 2017-02-22 | 西奈山伊坎医学院 | 受限制的三环磺酰胺 |
| CN108349961B (zh) | 2015-09-09 | 2022-02-18 | 西奈山伊坎医学院 | 杂环受限三环磺酰胺作为抗癌试剂 |
| WO2021150695A1 (en) * | 2020-01-22 | 2021-07-29 | Icahn School Of Medicine At Mount Sinai | Constrained n-substituted tetrahydrobenzoazepine sulfonamides as anticancer and neuroprotective agents |
| US20230020161A1 (en) * | 2020-02-28 | 2023-01-19 | Rappta Therapeutics Oy | Tricyclic Modulators of PP2A |
| EP4121031A4 (en) * | 2020-03-20 | 2024-03-27 | Atux Iskay LLC | 3-DIARYLMETHYLENE AND THEIR USE |
| CN114272378B (zh) * | 2020-09-27 | 2023-06-23 | 四川大学华西医院 | 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途 |
| AU2022216880A1 (en) * | 2021-02-08 | 2023-08-10 | Rappta Therapeutics Oy | Substituted cyclic modulators of protein phosphatase 2a (pp2a) and methods using same |
| US20240368105A1 (en) | 2021-08-18 | 2024-11-07 | Atux Iskay Llc | 2-diarylmethyl-4-aminotetrahydropyran derivatives and related compounds as anticancer, antiinflammatory, antifibrotic and neuroprotective agents |
| IL318597A (en) * | 2022-08-04 | 2025-03-01 | Rappta Therapeutics Oy | Aromatic compounds for use as modulators of protein phosphatase 2A (PP2A) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634766A (en) | 1983-10-31 | 1987-01-06 | Merck Frosst Canada, Inc. | 1,4-diaza-phenothiazines |
| GB8510680D0 (en) | 1985-04-26 | 1985-06-05 | Smith Kline French Lab | Pyridine derivatives |
| US4882351A (en) | 1987-10-14 | 1989-11-21 | Roussel Uclaf | Tricyclic compounds |
| DE69431470T2 (de) | 1993-07-26 | 2003-08-14 | Eisai Co., Ltd. | Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring |
| WO1997030038A1 (en) | 1996-02-15 | 1997-08-21 | Mitsubishi Chemical Corporation | Diarylsultam derivatives |
| US6333322B1 (en) | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| AU2641899A (en) | 1998-02-27 | 1999-09-15 | Eisai Co. Ltd. | Heterocycle-fused benzothiazine derivatives |
| AR031612A1 (es) | 2000-09-20 | 2003-09-24 | Schering Corp | Imidazoles sustituidos, composiciones farmaceuticas, metodo para su preparacion y el uso de los mismos para preparar un medicamento como agonistas o antagonistas h1 y h3 de histamina |
| EP1481673A4 (en) | 2002-02-05 | 2008-09-24 | Ajinomoto Kk | MEDICAL COMPOSITIONS WITH GABAPENTIN OR PREGABALINE AND N-TYPE CALCIUM CHANNEL ANTAGONIST |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| CA2587664A1 (en) | 2004-12-21 | 2006-06-29 | Devgen N.V. | Compounds with kv4 ion channel activity |
| IT1362675B (it) | 2005-03-15 | 2009-06-25 | Menarini Internat Operations Luxembourg Sa | N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche |
| ES2477868T3 (es) | 2005-04-22 | 2014-07-18 | Alantos Pharmaceuticals Holding, Inc. | Inhibidores de dipeptidil peptidasa-IV |
| GB0508992D0 (en) | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| WO2008121859A1 (en) | 2007-03-30 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions |
| CN103889981B (zh) | 2011-08-16 | 2016-11-09 | 西奈山伊坎医学院 | 作为抗癌剂的三环化合物 |
| WO2014031986A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| CN102942562B (zh) | 2012-12-05 | 2014-10-01 | 天津市斯芬克司药物研发有限公司 | 一种苯并咪唑衍生物及其制备方法和应用 |
| CA2901493A1 (en) * | 2013-02-19 | 2014-08-28 | Icahn School Of Medicine At Mount Sinai | Tricyclic heterocycles as anticancer agents |
| WO2015138500A1 (en) | 2014-03-11 | 2015-09-17 | Icahn School Of Medicine At Mount Sinai | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents |
| CN106458916A (zh) | 2014-03-11 | 2017-02-22 | 西奈山伊坎医学院 | 受限制的三环磺酰胺 |
| EP3331867A1 (en) | 2015-08-06 | 2018-06-13 | Icahn School of Medicine at Mount Sinai | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols |
| WO2017044572A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Ring constrained diarylamino sulfonamides as anti-cancer agents |
| WO2017044571A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Tricyclic sultam sulfonamides as anticancer and neuroprotective agents |
| WO2017044575A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents |
| CN108349961B (zh) | 2015-09-09 | 2022-02-18 | 西奈山伊坎医学院 | 杂环受限三环磺酰胺作为抗癌试剂 |
-
2016
- 2016-09-08 CA CA2997769A patent/CA2997769A1/en not_active Abandoned
- 2016-09-08 CN CN201680063247.5A patent/CN108349943A/zh active Pending
- 2016-09-08 EP EP16766784.9A patent/EP3347350A1/en not_active Ceased
- 2016-09-08 WO PCT/US2016/050685 patent/WO2017044567A1/en not_active Ceased
- 2016-09-08 US US15/758,038 patent/US10221158B2/en active Active
- 2016-09-08 JP JP2018512944A patent/JP6966425B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20180251444A1 (en) | 2018-09-06 |
| US10221158B2 (en) | 2019-03-05 |
| WO2017044567A1 (en) | 2017-03-16 |
| JP6966425B2 (ja) | 2021-11-17 |
| JP2018526416A (ja) | 2018-09-13 |
| CN108349943A (zh) | 2018-07-31 |
| EP3347350A1 (en) | 2018-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2997769A1 (en) | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents | |
| EP3116860B1 (en) | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents | |
| EP3116857B1 (en) | Constrained tricyclic sulfonamides | |
| WO2017044575A1 (en) | Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents | |
| EP3347355B1 (en) | Heterotricyclic sulfonamides as anti-cancer agents | |
| EP2744808A2 (en) | Tricyclic compounds as anticancer agents | |
| WO2017044571A1 (en) | Tricyclic sultam sulfonamides as anticancer and neuroprotective agents | |
| WO2017044572A1 (en) | Ring constrained diarylamino sulfonamides as anti-cancer agents | |
| CA3226162A1 (en) | Aryl compounds and pharmaceutical compositions that modulate ikzf2 | |
| WO2021150697A1 (en) | N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents | |
| WO2021150695A1 (en) | Constrained n-substituted tetrahydrobenzoazepine sulfonamides as anticancer and neuroprotective agents | |
| AU2014219042A1 (en) | Tricyclic heterocycles as anticancer agents | |
| WO2024040045A2 (en) | 2-diarylmethyl-4-aminotetrahydropyran sulfonimidamides as anticancer, antiinflammatory, antifibrotic and neuroprotective agents | |
| US12522575B2 (en) | 2-diarylmethyl-4-aminotetrahydropyran derivatives and related compounds as anticancer, antiinflammatory, antifibrotic and neuroprotective agents | |
| TW202345806A (zh) | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 | |
| WO2021150700A1 (en) | N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210816 |
|
| EEER | Examination request |
Effective date: 20210816 |
|
| EEER | Examination request |
Effective date: 20210816 |
|
| EEER | Examination request |
Effective date: 20210816 |
|
| EEER | Examination request |
Effective date: 20210816 |
|
| FZDE | Discontinued |
Effective date: 20240214 |